2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.
Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma (MCL).
Although oral BTK inhibitors, such as ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa), have transformed the treatment paradigm of MCL, some patients with high-risk disease do not respond to these agents, says Shah. In addition, these patients are unlikely to respond to chemotherapy, Shah explains.
High-risk MCL is often characterized by p53 mutations, high Ki-67 expression over 50%, and blastoid or pleomorphic morphology, Shah says. As BTK inhibitors and chemotherapy are not suitable treatment options for this patient population, novel therapies and combinations strategies are needed, concludes Shah.
Related Content: